Immunome, Inc.
Immunome, Inc. (IMNM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IMNM · as of Sep 30, 2025
Ownership Breakdown
164
Institutional Holders
▲ 16 vs Q2
$1.07B
Total Inst. Value
▲ $331.43M vs Q2
95.60M
Shares Outstanding
freeFloat 82.90%
91.38M
13F Shares Held
▲ 11.95M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IMNM largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 13.06M | 15.01% | 15.01% | $152.89B | Nov 13, 2025 | ▲ 6.89M |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. pharmaceutical preparations | 8.42M | 9.67% | 9.67% | $98.58B | Nov 14, 2025 | ▲ 142.9K |
BLACKROCK, INC. pharmaceutical preparations | 5.82M | 6.69% | 6.69% | $68.18B | Nov 12, 2025 | ▲ 52.0K |
REDMILE GROUP, LLC pharmaceutical preparations | 5.02M | 5.77% | 5.77% | $58.82B | Nov 14, 2025 | ▲ 151.2K |
VANGUARD GROUP INC pharmaceutical preparations | 4.89M | 5.62% | 5.62% | $57.30B | Nov 7, 2025 | ▲ 368.7K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 4.82M | 5.54% | 5.54% | $56.49B | Nov 14, 2025 | ▲ 138.7K |
ENAVATE SCIENCES GP, LLC pharmaceutical preparations | 4.77M | 5.48% | 5.48% | $55.84B | Nov 14, 2025 | — held |
ECOR1 CAPITAL, LLC pharmaceutical preparations | 4.08M | 4.69% | 4.69% | $47.77B | Nov 14, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 3.74M | 4.30% | 4.30% | $43.83B | Nov 14, 2025 | ▲ 760.7K |
OPALEYE MANAGEMENT INC. pharmaceutical preparations | 3.19M | 3.66% | 3.66% | $37.30B | Nov 14, 2025 | ▼ 344.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
33
Increased
+16.20M shares3
New Positions
first time holders12
Decreased
−4.40M shares0
Sold Out
fully exitedNet shares change (top 50)
+11.80M
+16.20M / −4.40M
Net new holders
+24
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IMNM insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
5
Sell transactions
0.40
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
BIENAIME JEAN JACQUES director | May 15, 2026 | Purchase | 5,000 | $20.70 | $103.5K | 43.4K | Form 4 ↗ |
Higgins Jack Chief Scientific Officer | Apr 2, 2026 | Sale | 9,438 | $21.64 | $204.2K | 22.0K | Form 4 ↗ |
Rosett Max Chief Financial Officer | Apr 2, 2026 | Sale | 63,656 | $21.91 | $1.39M | 55.4K | Form 4 ↗ |
Rosett Max Chief Financial Officer | Apr 2, 2026 | Sale | 1,344 | $22.48 | $30.2K | 54.0K | Form 4 ↗ |
Higgins Jack Chief Scientific Officer | Mar 30, 2026 | Gift | 6,291 | — | — | 31.4K | Form 4 ↗ |
SIEGALL CLAY B President and CEO | Mar 27, 2026 | Purchase | 25,450 | $19.67 | $500.6K | 690.7K | Form 4 ↗ |
WAGENHEIM PHILIP director | Mar 20, 2026 | Sale | 36,800 | $20.47 | $753.3K | 369.3K | Form 4 ↗ |
WAGENHEIM PHILIP director | Mar 23, 2026 | Sale | 28,200 | $20.65 | $582.3K | 341.1K | Form 4 ↗ |
BIENAIME JEAN JACQUES director | Mar 11, 2026 | Purchase | 1,000 | $21.55 | $21.6K | 38.4K | Form 4 ↗ |
BIENAIME JEAN JACQUES director | Mar 10, 2026 | Purchase | 1,000 | $22.12 | $22.1K | 37.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Immunome, Inc. (IMNM) is primarily owned by institutional investors, who hold approximately 95.6% of total shares outstanding. Company insiders own approximately 17.10%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Immunome, Inc. is FMR LLC, holding approximately 13.06 million shares — equal to 15.01% of outstanding shares — as of September 30, 2025.
A total of 164 institutional investors currently hold IMNM stock, with a combined institutional value of approximately $1.07 billion as of the most recent 13F filing period.
Frequently asked questions
IMNM ownershipImmunome, Inc. (IMNM) is primarily owned by institutional investors, who hold approximately 95.6% of shares. The largest shareholder is FMR LLC with a 15.01% stake. Company insiders hold 17.10%. Data sourced from SEC Form 13F as of September 30, 2025.